Quarterly ResultAug 13, 2026, 08:07 AM
Bluejay Diagnostics Q2 Cash $9.6M; SYMON-II Enrollment Complete
AI Summary
Bluejay Diagnostics reported its second quarter 2026 financial results, ending the period with approximately $9.6 million in cash and cash equivalents, up from $5.2 million at year-end 2025. The company strengthened its financial position through $7.7 million in net cash from financing activities, including a $7.6 million private placement in June 2026, which is expected to fund operations through Q2 2027. Operationally, Bluejay completed targeted enrollment of 750 patients in its SYMON-II pivotal clinical study for the Symphony™ IL-6 test and signed a US manufacturing contract, advancing towards planned FDA 510(k) submission and commercialization.
Key Highlights
- SYMON-II pivotal clinical study completed targeted enrollment of 750 patients.
- Signed US manufacturing contract to mitigate supply-chain risk for Symphony™ IL-6.
- Ended Q2 2026 with approximately $9.6 million in cash and cash equivalents.
- Cash and cash equivalents were approximately $5.2 million at December 31, 2025.
- Generated approximately $7.7 million net cash from financing activities in H1 2026.
- Received approximately $7.6 million net proceeds from June 2026 private placement.
- Current cash resources are estimated to fund operations through Q2 2027.
Price Impact
More from BJDX